| Source: |
| Type: |
| CA pH Control, Hypoxia Adaptation, and Metastatic Fitness
Family of enzymes that catalyze the reversible hydration of carbon dioxide (CO₂) to bicarbonate (HCO₃⁻) and a proton (H⁺). Carbonic Anhydrase IX (CAIX) is a well-described enzyme in renal cell carcinoma, with its expression being regulated by the hypoxia-inducible factor 1 alpha, it is known for interfering with hypoxia processes. Carbonic anhydrase 9 (CA9) is a protein to be upregulated under exposure to hypoxic conditions. Hypoxic conditions are known to be associated with resistance to chemotherapy and radiotherapy, and with poor cancer prognosis. Of the carbonic anhydrases, CA9 and CA12, are transmembrane isozymes that are highly expressed in some tumours, and may be implicated in acidification of the extracellular milieu surrounding cancer cells, thus creating a microenvironment conducive to tumour growth and spread. Carbonic anhydrase IX, is an endogenous marker for hypoxia. |
| 5314- | acetaz, | Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment |
| - | Review, | Var, | NA |
| 5964- | CEL, | Celecoxib pathways: pharmacokinetics and pharmacodynamics |
| - | Review, | Var, | NA |
| 5962- | CEL, | The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II |
| - | Study, | Var, | NA |
| 5961- | CEL, | Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer |
| - | Review, | Var, | NA |
| 5958- | CEL, | Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition |
| - | in-vitro, | Var, | NA |
| 5956- | CEL, | Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy |
| - | Review, | Var, | NA |
| 972- | MAG, | Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells |
| - | vitro+vivo, | Bladder, | T24/HTB-9 |
| 3282- | SIL, | Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions |
| - | Review, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:37 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid